The role of basket trials in drug development for neurodegenerative disorders

Background Drug development for neurodegenerative disorders (NDDs) is a long, complex, and expensive enterprise.

Methods to optimize drug development for NDDs are needed.

Basket trials have been widely used in oncology and have been promoted by the Food and Drug Administration as a means of enhancing the efficiency of drug development.

Discussion We reviewed clinical trials for NDDs registered on clinicaltrials.gov in the past 10 years.

We identified 59 basket trials assessing the impact of treatment on more than one NDD in the trial.

Forty-one of the trials were for 25 agents addressing symptoms of NDD such as motor impairment, hypotension, or psychosis.

Eighteen of the trials assessed 14 disease-modifying therapies; the principal targets were mitochondrial function, tau biology, or alpha-synuclein aggregation.

Basket trials are most common in phase 2 but have been conducted in phase 1, phase 3, and phase 4.

The duration and size of the basket trials are highly variable depending on their developmental phase and the intent of the trial.

Parkinson’s disease was the most common disorder included in basket trials of symptomatic agents, and Alzheimer’s disease was the most common disorder included in basket trials of disease-modifying therapies.

Most of the basket trials of symptomatic agents were sponsored by pharmaceutical companies (29 of 41 trials); similarly, most of the basket trials investigating DMTs in basket trials were sponsored by the biopharmaceutical industry (11/17 trials).

Conclusions Basket trials may increase drug development efficiency by reducing redundancy in trial implementation, enhancing recruitment, sharing placebo groups, and using biomarkers relevant to the mechanism of action of the treatment across NDDs.

There have been relatively few basket trials including multiple NDDs in the same trial conducted over the past 10 years.

The use of the basket trial strategy may represent an opportunity to increase the efficiency of development programs for agents to treat NDDs.